CN101798298B - 咪唑衍生物 - Google Patents

咪唑衍生物 Download PDF

Info

Publication number
CN101798298B
CN101798298B CN2010101215002A CN201010121500A CN101798298B CN 101798298 B CN101798298 B CN 101798298B CN 2010101215002 A CN2010101215002 A CN 2010101215002A CN 201010121500 A CN201010121500 A CN 201010121500A CN 101798298 B CN101798298 B CN 101798298B
Authority
CN
China
Prior art keywords
methyl
phenyl
imidazol
methanol
imidazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2010101215002A
Other languages
English (en)
Chinese (zh)
Other versions
CN101798298A (zh
Inventor
A·阿兰因
B·布特尔曼
M-P·海茨内德哈特
G·耶施克
E·皮纳德
R·维勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ethiopia Wodtke International Co Ltd
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN101798298A publication Critical patent/CN101798298A/zh
Application granted granted Critical
Publication of CN101798298B publication Critical patent/CN101798298B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN2010101215002A 2001-01-29 2002-01-21 咪唑衍生物 Expired - Fee Related CN101798298B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01101947.8 2001-01-29
EP01101947 2001-01-29

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN028042557A Division CN1489580B (zh) 2001-01-29 2002-01-21 咪唑衍生物

Publications (2)

Publication Number Publication Date
CN101798298A CN101798298A (zh) 2010-08-11
CN101798298B true CN101798298B (zh) 2013-01-09

Family

ID=8176317

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2010101215002A Expired - Fee Related CN101798298B (zh) 2001-01-29 2002-01-21 咪唑衍生物
CN028042557A Expired - Fee Related CN1489580B (zh) 2001-01-29 2002-01-21 咪唑衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN028042557A Expired - Fee Related CN1489580B (zh) 2001-01-29 2002-01-21 咪唑衍生物

Country Status (23)

Country Link
US (3) US6610723B2 (OSRAM)
EP (1) EP1358165B1 (OSRAM)
JP (1) JP4094956B2 (OSRAM)
KR (1) KR100619106B1 (OSRAM)
CN (2) CN101798298B (OSRAM)
AR (1) AR035422A1 (OSRAM)
AT (1) ATE425147T1 (OSRAM)
BR (1) BR0206758A (OSRAM)
CA (1) CA2434813C (OSRAM)
CY (1) CY1110265T1 (OSRAM)
DE (1) DE60231477D1 (OSRAM)
DK (1) DK1358165T3 (OSRAM)
ES (1) ES2319967T3 (OSRAM)
GC (1) GC0000318A (OSRAM)
GT (1) GT200200013A (OSRAM)
JO (1) JO2292B1 (OSRAM)
MX (1) MXPA03006773A (OSRAM)
MY (1) MY138334A (OSRAM)
PA (1) PA8537801A1 (OSRAM)
PE (1) PE20020917A1 (OSRAM)
PT (1) PT1358165E (OSRAM)
WO (1) WO2002060877A1 (OSRAM)
ZA (1) ZA200305626B (OSRAM)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005531548A (ja) * 2002-05-02 2005-10-20 ニューロジェン コーポレイション 置換イミダゾール誘導体:gabaa受容体リガンド
WO2005028467A1 (en) 2003-09-15 2005-03-31 Anadys Pharmaceuticals, Inc. Antibacterial 3,5-diaminopiperidine-substitute aromatic and heteroaromatic compounds
JP4836280B2 (ja) 2004-06-18 2011-12-14 ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド 癌を治療するためのキネシンスピンドルタンパク質(ksp)阻害剤としてのn−(1−(1−ベンジル−4−フェニル−1h−イミダゾール−2−イル)−2,2−ジメチルプロピル)ベンズアミド誘導体および関連化合物
ITRM20050094A1 (it) * 2005-03-04 2006-09-05 Univ Siena Derivati del 1-(1,5-di(4-clorofenil)-2metil-1h-3-pirroli)metil)-4-metilpiperazina (bm 212), procedimento per la loro produzione e uso di essi come antitubercolari.
EP1940822A1 (en) 2005-10-14 2008-07-09 NeuroSearch A/S Imidazole derivatives and their use for modulating the gaba-a receptor complex
KR100694181B1 (ko) * 2005-11-25 2007-03-12 연세대학교 산학협력단 근원세포 또는 근섬유로부터 신경세포 분화를 유도하는화합물, 이를 포함하는 약학적 조성물, 신경세포 분화를유도하는 방법 및 신경세포 분화를 유도하는 화합물을검색하는 스크리닝 방법
CN101711242B (zh) * 2007-05-23 2013-09-25 阿勒根公司 作为肾上腺素能受体激动剂的((二环杂芳基)咪唑基)甲基杂芳基化合物
WO2010009327A1 (en) * 2008-07-17 2010-01-21 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compounds for the treatment of pathologies associated with aging and degenerative disorders
BRPI0916576A2 (pt) 2008-08-04 2017-06-27 Chdi Inc pelo menos uma entidade química, composição farmacêutica, e, método para tratar uma condição ou distúrbio.
PH12012501480A1 (en) 2010-01-25 2012-10-22 Chdi Foundation Inc Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2011101457A1 (en) 2010-02-18 2011-08-25 B.R.A.I.N. Biotechnology Research And Information Network Ag Chimeric surface active proteins
EP2630136A1 (en) * 2010-10-21 2013-08-28 Universität des Saarlandes Selective cyp11b1 inhibitors for the treatment of cortisol dependent diseases
AU2012300246A1 (en) 2011-08-30 2014-03-06 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EP3243515B1 (en) 2011-08-30 2019-10-16 CHDI Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
US9199975B2 (en) 2011-09-30 2015-12-01 Asana Biosciences, Llc Biaryl imidazole derivatives for regulating CYP17
EP2760854B1 (en) * 2011-09-30 2017-08-30 Asana BioSciences, LLC Imidazole derivatives as cyp17 inhibitors for the treatment of cancer
US8809372B2 (en) 2011-09-30 2014-08-19 Asana Biosciences, Llc Pyridine derivatives
AP2017009724A0 (en) 2014-07-17 2017-01-31 Chdi Foundation Inc Methods and compositions for treating hiv-related disorders
JP6605020B2 (ja) * 2014-08-15 2019-11-13 ヤンセン ファーマシューティカルズ,インコーポレーテッド Nr2b受容体阻害剤としてのトリアゾール
HUE049278T2 (hu) * 2014-08-15 2020-09-28 Janssen Pharmaceuticals Inc Pirazolok
DE102015011861B4 (de) 2015-09-10 2018-03-01 Rudolf Schindler Neue cyclische Carboxamide als NMDA NR2B Rezeptor Inhibitoren
BR112018016329A2 (pt) 2016-02-10 2018-12-18 Janssen Pharmaceutica Nv 1,2,3-triazóis substituídos como moduladores de nmda seletivos para nr2b
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之1H-咪唑並[4,5-b]吡啶-2(3H)-酮及其作為GLUN2B受體調節劑之用途
TW201822637A (zh) 2016-11-07 2018-07-01 德商拜耳廠股份有限公司 用於控制動物害蟲的經取代磺醯胺類
CN112074505B (zh) 2018-03-08 2024-04-05 因赛特公司 作为PI3K-γ抑制剂的氨基吡嗪二醇化合物
JP7346441B2 (ja) 2018-04-04 2023-09-19 ヤンセン ファーマシューティカ エヌ.ベー. 置換ピリジン及びピリミジン並びにglun2b受容体調節物質としてのそれらの使用
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
KR20220024403A (ko) 2019-06-14 2022-03-03 얀센 파마슈티카 엔.브이. 치환된 피라졸로-피라진 및 이들의 glun2b 수용체 조절제로서의 용도
JP7667097B2 (ja) 2019-06-14 2025-04-22 ヤンセン ファーマシューティカ エヌ.ベー. 置換ピラゾロ-ピリジンアミド及びglun2b受容体調節因子としてのその使用
BR112021025141A2 (pt) 2019-06-14 2022-01-25 Janssen Pharmaceutica Nv Pirazolo-piridinas heteroaromáticas substituídas e seu uso como moduladores do receptor glun2b
CA3142998A1 (en) 2019-06-14 2020-12-17 Janssen Pharmaceutica Nv Pyrazine carbamates and their use as glun2b receptor modulators
US11618750B2 (en) 2019-06-14 2023-04-04 Janssen Pharmaceutica Nv Substituted pyrazolo-pyridine amides and their use as GluN2B receptor modulators
CA3143102A1 (en) 2019-06-14 2020-12-17 Janssen Pharmaceutica Nv Substituted pyrazolo[4,3-b]pyridines and their use as glun2b receptor modulators
MX2021015508A (es) 2019-06-14 2022-01-31 Janssen Pharmaceutica Nv Carbamatos de piridina y su uso como moduladores del receptor glun2b.
CN115656401B (zh) * 2022-11-09 2025-03-28 武汉海特生物创新医药研究有限公司 一种咪唑-4-甲酸乙酯纯度的hplc检测方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1088925A (zh) * 1993-01-02 1994-07-06 山道士有限公司 咪唑基甲基吡啶

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3627155A1 (de) 1986-08-11 1988-02-18 Schering Ag Imidazol-derivate
US5872136A (en) * 1996-04-03 1999-02-16 Merck & Co., Inc. Arylheteroaryl inhibitors of farnesyl-protein transferase
US5998424A (en) * 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
IT1300055B1 (it) 1998-04-17 2000-04-05 Boehringer Ingelheim Italia Eterocicli con anello a 5 termini difenil-sostituiti loro procedimento di preparazione e loro impiego come farmici
DK1070708T3 (da) 1999-07-21 2004-05-10 Hoffmann La Roche Triazolderivater

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1088925A (zh) * 1993-01-02 1994-07-06 山道士有限公司 咪唑基甲基吡啶

Also Published As

Publication number Publication date
CN1489580A (zh) 2004-04-14
HK1146646A1 (en) 2011-06-24
BR0206758A (pt) 2004-02-17
PT1358165E (pt) 2009-04-22
DK1358165T3 (da) 2009-05-11
CN101798298A (zh) 2010-08-11
MXPA03006773A (es) 2003-10-24
KR20030070615A (ko) 2003-08-30
CY1110265T1 (el) 2015-01-14
WO2002060877A1 (en) 2002-08-08
JO2292B1 (en) 2005-09-12
AR035422A1 (es) 2004-05-26
EP1358165A1 (en) 2003-11-05
ZA200305626B (en) 2004-10-21
DE60231477D1 (en) 2009-04-23
US20020151715A1 (en) 2002-10-17
US20030191311A1 (en) 2003-10-09
ATE425147T1 (de) 2009-03-15
US6667335B2 (en) 2003-12-23
US6683097B2 (en) 2004-01-27
JP2004523535A (ja) 2004-08-05
US6610723B2 (en) 2003-08-26
KR100619106B1 (ko) 2006-09-01
GT200200013A (es) 2002-09-02
CA2434813A1 (en) 2002-08-08
ES2319967T3 (es) 2009-05-18
PA8537801A1 (es) 2002-09-17
CA2434813C (en) 2009-12-22
JP4094956B2 (ja) 2008-06-04
US20030187268A1 (en) 2003-10-02
EP1358165B1 (en) 2009-03-11
PE20020917A1 (es) 2002-10-19
HK1063794A1 (en) 2005-01-14
CN1489580B (zh) 2010-05-26
MY138334A (en) 2009-05-29
GC0000318A (en) 2006-11-01

Similar Documents

Publication Publication Date Title
CN101798298B (zh) 咪唑衍生物
JP3564133B2 (ja) ▲iv▼型ホスホジェステラーゼ阻害因子としてのキノリン類
DE69736642T2 (de) Heterocyclische Verbindungen, ihre Herstellung und Verwendung
EP1194144B1 (en) Antibacterial compounds
US5332831A (en) Benzofuran derivatives
US5998437A (en) Benzimidazole derivatives
CA2129146A1 (en) Imidazole, triazole and tetrazole derivatives
CN101835752A (zh) 用于治疗癌症和银屑病的杂环酰胺
CZ303101B6 (cs) Prípravek podporující tvorbu/sekreci neurotropinu
CA2643011A1 (en) Quinolones useful as inducible nitric oxide synthase inhibitors
DE69810760T2 (de) Verbindungen mit kondensierten ringen, verfahren zu ihrer herstellung und ihre anwendung
US20080214622A1 (en) Substituted Triazole Derivatives As Oxytocin Antagonists
KR870000548B1 (ko) 3-카르보닐-1-아미노알킬-1 h-인돌의 제조방법
US5922718A (en) Triazolones as apolipoprotein-B synthesis inhibitors
JP2003277379A (ja) 含窒素複素環化合物、その製造法および用途
US6248768B1 (en) Benzimidazole derivatives and pharmacologically acceptable salts thereof
AU2002246043B2 (en) Imidazole derivatives
HK1146646B (en) Imidazole derivatives
HK1063794B (en) Imidazole derivatives
AU2002246043A1 (en) Imidazole derivatives
TWI328584B (en) Imidazole derivatives
AU2016366443A1 (en) Aminoazole derivative
ME01934B (me) Derivati pirazola kao modulatori protein kinaze
JPWO2001030764A1 (ja) 1−置換フェニル−1−(1h−イミダゾール−4−イル)アルコール類、その製造法および用途
TW201307294A (zh) 雜環化合物及其用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1146646

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1146646

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: EVOTEC INTERNATIONAL GMBH

Free format text: FORMER OWNER: F. HOFFMANN-LA ROCHE AG

Effective date: 20130826

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20130826

Address after: hamburg

Patentee after: Ethiopia wodtke International Co. Ltd.

Address before: Basel

Patentee before: F. Hoffmann-La Roche AG

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130109

Termination date: 20170121

CF01 Termination of patent right due to non-payment of annual fee